Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Pharma Holdings ( (CPHI) ) has issued an announcement.
On December 4, 2025, China Pharma Holdings‘ subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Lijie Tang for the acquisition of an invention patent on Captopril microcapsules. The transfer, valued at $6.3 million, will be compensated through the issuance of 3,500,000 shares of the company’s common stock, highlighting a strategic move to enhance its pharmaceutical offerings.
The most recent analyst rating on (CPHI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on China Pharma Holdings stock, see the CPHI Stock Forecast page.
Spark’s Take on CPHI Stock
According to Spark, TipRanks’ AI Analyst, CPHI is a Neutral.
The overall stock score of 48 reflects significant financial challenges faced by China Pharma Holdings, with negative profitability and cash flow metrics being the most impactful factors. While there is some positive technical momentum, the valuation metrics are concerning due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data means these factors do not influence the score.
To see Spark’s full report on CPHI stock, click here.
More about China Pharma Holdings
China Pharma Holdings, Inc. operates in the medical and biotechnology industry through its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. The company focuses on developing and providing pharmaceutical products and related services.
Average Trading Volume: 14,129
Technical Sentiment Signal: Sell
Current Market Cap: $8.74M
See more insights into CPHI stock on TipRanks’ Stock Analysis page.